{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:45:09Z","timestamp":1775025909748,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1007\/s11926-001-0048-8","type":"journal-article","created":{"date-parts":[[2007,6,9]],"date-time":"2007-06-09T05:03:24Z","timestamp":1181365404000},"page":"29-35","source":"Crossref","is-referenced-by-count":37,"title":["Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient"],"prefix":"10.1007","volume":"3","author":[{"given":"Adel G.","family":"Fam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0889-857X(21)00975-3","volume":"14","author":"SL Wallace","year":"1988","unstructured":"Wallace SL, Singer, SZ: Therapy in gout. Rheum Dis Clin North Am 1988, 14:441\u2013457.","journal-title":"Rheum Dis Clin North Am"},{"key":"48_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/00002512-199813030-00006","volume":"13","author":"AG Fam","year":"1998","unstructured":"Fam AG: Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998, 13:229\u2013243. A comprehensive review outlining the management of gout.","journal-title":"Drugs Aging"},{"key":"48_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1056\/NEJM199602153340707","volume":"334","author":"BT Emmerson","year":"1996","unstructured":"Emmerson BT: The management of gout. N Engl J Med 1996, 334:445\u2013451. A detailed overview of the treatment of gout.","journal-title":"N Engl J Med"},{"key":"48_CR4","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/archinte.145.8.1492","volume":"145","author":"RW Rundles","year":"1985","unstructured":"Rundles RW: The development of allopurinol. Arch Intern Med 1985, 145:1492\u20131503.","journal-title":"Arch Intern Med"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","volume":"40","author":"GT McInnes","year":"1981","unstructured":"McInnes GT, Lawson DH, Jick H: Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 1981, 40:245\u2013249.","journal-title":"Ann Rheum Dis"},{"key":"48_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47\u201356.","journal-title":"Am J Med"},{"key":"48_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/art.1780290111","volume":"29","author":"JZ Singer","year":"1986","unstructured":"Singer JZ, Wallace SL: The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986, 29:82\u201387.","journal-title":"Arthritis Rheum"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","volume":"27","author":"F Arellano","year":"1993","unstructured":"Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacotherapy 1993, 27:337\u2013343. A review of allopurinol hypersensitivity syndrome.","journal-title":"Ann Pharmacotherapy"},{"key":"48_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000248097","volume":"179","author":"SH Chan","year":"1989","unstructured":"Chan SH, Tan T: HLA and allopurinol drug eruption. Dermatologica 1989, 179:32\u201333.","journal-title":"Dermatologica"},{"key":"48_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/rheumatology\/38.12.1301","volume":"38","author":"RD Melson","year":"1999","unstructured":"Melson RD: Familial hypersensitivity to allopurinol with subsequent desensitization [letter]. Rheumatology 1999, 38:1301.","journal-title":"Rheumatology"},{"key":"48_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/art.1780310318","volume":"31","author":"BT Emmerson","year":"1988","unstructured":"Emmerson BT, Hazelton RA, Frazer IH: Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxipurinol. Arthritis Rheum 1988, 31:436\u2013440.","journal-title":"Arthritis Rheum"},{"key":"48_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/clin.1994.1022","volume":"70","author":"GL Braden","year":"1994","unstructured":"Braden GL, Warzynski MJ, Golightly M, Ballow M: Cellmediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994, 70:145\u2013151.","journal-title":"Clin Immunol Immunopathol"},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.155.1.462","volume":"155","author":"D Mauri-Hellweg","year":"1995","unstructured":"Mauri-Hellweg D, Bettens F, Mauri D, et al.: Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995, 155:462\u2013472.","journal-title":"J Immunol"},{"key":"48_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ndt\/14.3.780","volume":"14","author":"D Morel","year":"1999","unstructured":"Morel D, Guez S, Merville P, et al.: Recurrent renal failure associated with hypersensitivity to allopurinol. Nephrol Dial Transplant 1999:14:780\u2013781.","journal-title":"Nephrol Dial Transplant"},{"key":"48_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archderm.134.9.1108","volume":"134","author":"Y Suzuki","year":"1998","unstructured":"Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T: Human herpesvirus 6 infection as a risk factor for the development of severe drug induced hypersensitivity syndrome. Arch Dermatol 1998, 134:1108\u20131112. The report suggests that reactivation of human herpesvirus 6 may play a role in the development of severe allopurinol hypersensitivity syndrome.","journal-title":"Arch Dermatol"},{"key":"48_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1046\/j.1365-4362.1999.00792.x","volume":"38","author":"S Halevy","year":"1999","unstructured":"Halevy S, Cohen AD, Livni E: The diagnostic role of the in vitro drug-induced interferon-g release test in Stevens-Johnson syndrome. Internat J Dermatol 1999, 38:835\u2013840. An interesting investigation suggesting that in vitro allopurinol-induced release of interferon-g from peripheral blood T-lymphocytes may be useful in the diagnosis of Stevens-Johnson syndrome and other sensitivity reactions to allopurinol.","journal-title":"Internat J Dermatol"},{"key":"48_CR17","first-page":"1841","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J: A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988, 15:1841\u20131847.","journal-title":"J Rheumatol"},{"key":"48_CR18","first-page":"1813","volume":"46","author":"SC Zell","year":"1989","unstructured":"Zell SC, Carmichael JM: Evaluation of allopurinol use in patients with gout. Am J Hosp Pharmacy 1989, 46:1813\u20131816.","journal-title":"Am J Hosp Pharmacy"},{"key":"48_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0002-9343(98)00323-4","volume":"105","author":"RL Wortmann","year":"1998","unstructured":"Wortmann RL: Effective management of gout: an analogy. Am J Med 1998, 105:513\u2013514. A practical approach to the treatment of gout.","journal-title":"Am J Med"},{"key":"48_CR20","first-page":"423","volume":"45","author":"MT Kovalchik III","year":"1981","unstructured":"Kovalchik III MT: Sulfinpyrazone induced uric acid urolithiasis with renal failure. Conn Med 1981, 45:423\u2013424.","journal-title":"Conn Med"},{"key":"48_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/BF00860751","volume":"9","author":"DP Jones","year":"1995","unstructured":"Jones DP, Mahmoud H, Chesney RW: Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995, 9:206\u2013212.","journal-title":"Pediatr Nephrol"},{"key":"48_CR22","first-page":"147","volume":"28","author":"JM Earll","year":"1983","unstructured":"Earll JM, Saavedra M: Oxypurinol therapy in allopurinolallergic patients. Am Fam Physician 1983, 28:147\u2013148.","journal-title":"Am Fam Physician"},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-85-3-333","volume":"85","author":"O Jr Lockard","year":"1976","unstructured":"Lockard O Jr, Harmon C, Nolph K, Irvin W: Allergic reaction to allopurinol with cross-reactivity to oxipurinol. Ann Intern Med 1976, 85:333\u2013335.","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"48_CR24","first-page":"S159","volume":"36","author":"JD O\u2019Duffy","year":"1993","unstructured":"O\u2019Duffy JD: Oxipurinol therapy in allopurinol-sensitive patients [abstract]. Arthritis Rheum 1993, 36(suppl):S159.","journal-title":"Arthritis Rheum"},{"key":"48_CR25","first-page":"51","volume":"3","author":"GB Elion","year":"1974","unstructured":"Elion GB: Drugs in the treatment of hyperuricemia. Adv Nephrol 1974, 3:51\u201357.","journal-title":"Adv Nephrol"},{"key":"48_CR26","first-page":"353","volume":"35","author":"RA Chalmars","year":"1968","unstructured":"Chalmars RA, Kromer H, Scott JT, Watts RWE: A comparative study of the xanthine oxidase inhibitors allopurinol and oxipurinol in man. Clin Sci 1968, 35:353\u2013362.","journal-title":"Clin Sci"},{"key":"48_CR27","first-page":"498","volume":"23","author":"I Walter-Sack","year":"1996","unstructured":"Walter-Sack I, de Vries JX, Ernst B, et al.: Uric acid lowering effect of oxipurinol sodium in hyperuricemia patients-therapeutic equivalence to allopurinol. J Rheumatol 1996, 23:498\u2013501.","journal-title":"J Rheumatol"},{"key":"48_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0022-3476(82)80259-X","volume":"100","author":"G Masera","year":"1982","unstructured":"Masera G, Jankovic M, Zurlo MG, et al.: Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982, 100:152\u2013155.","journal-title":"J Pediatr"},{"key":"48_CR29","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","volume":"11","author":"C-H Pui","year":"1997","unstructured":"Pui C-H, Relling MV, Lascombes F, et al.: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997, 11:1813\u20131816.","journal-title":"Leukemia"},{"key":"48_CR30","first-page":"2171","volume":"20","author":"S Rozenberg","year":"1993","unstructured":"Rozenberg S, Koeger A-C, Bougeois P: Urate oxidase for gouty arthritis in cardiac transplant recipients [letter]. J Rheumatol 1993, 20:2171.","journal-title":"J Rheumatol"},{"key":"48_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(81)90528-6","volume":"2","author":"S Davis","year":"1981","unstructured":"Davis S, Park YK, Abuchowski A, Davis FF: Hypouricemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981, 2:281\u2013283.","journal-title":"Lancet"},{"issue":"suppl:4","key":"48_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.1998.432","volume":"77","author":"HH Mahmoud","year":"1998","unstructured":"Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F: Advances in the management of malignancy-associated hyperuricemia. Br J Cancer 1998, 77(suppl:4):18\u201320. A preliminary investigation of a potent recombinant urate oxidase (uricase) used in the prophylaxis and treatment of chemotherapy-associated hyperuricemia in patients with leukemia, lymphoma and myeloma.","journal-title":"Br J Cancer"},{"key":"48_CR33","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1126\/science.3344434","volume":"239","author":"CC Lee","year":"1988","unstructured":"Lee CC, Wu X, Gibbs RA, et al.: Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. Science 1988, 239:1288\u20131291.","journal-title":"Science"},{"key":"48_CR34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-109-2-114","volume":"109","author":"CC Chua","year":"1988","unstructured":"Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 109:114\u2013117.","journal-title":"Ann Intern Med"},{"key":"48_CR35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ndt\/9.5.548","volume":"9","author":"RM Zurcher","year":"1994","unstructured":"Zurcher RM, Bock HA, Thiel G: Excellent uricosuric efficacy of benzbromarone in cyclosporine-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994, 9:548\u2013551.","journal-title":"Nephrol Dial Transplant"},{"key":"48_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4615-5381-6_4","volume":"431","author":"R Grahame","year":"1998","unstructured":"Grahame R, Simmonds HA, McBride MB, Marsh FP: How should we treat tophaceous gout in patients with allopurinol hypersensitivity? Adv Exp Med Biol 1998, 431:19\u201323.","journal-title":"Adv Exp Med Biol"},{"key":"48_CR37","first-page":"49","volume":"5","author":"F Perez-Ruiz","year":"1999","unstructured":"Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al.: Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. JCR: J Clin Rheumatol 1999, 5:49\u201355. A reappraisal of benzbromarone in the treatment of chronic gout in patients with renal impairment.","journal-title":"JCR: J Clin Rheumatol"},{"key":"48_CR38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz, F, Alonzo-Ruiz A, Calabozo M, et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545\u2013549.","journal-title":"Ann Rheum Dis"},{"key":"48_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF00315283","volume":"44","author":"OF Muller","year":"1993","unstructured":"Muller OF, Schall R, Groenewoud G, et al.: The effect of benzbromarone on allopurinol\/oxipurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993, 44:69\u201372.","journal-title":"Eur J Clin Pharmacol"},{"key":"48_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/clpt.1993.112","volume":"54","author":"SD Saris","year":"1993","unstructured":"Saris SD, Piraino AJ, Morgan JM, et al.: Uricosuric effects of CGS-12970, a new thromboxane synthase inhibitor. Clin Pharm Ther 1993, 54:65\u20139.","journal-title":"Clin Pharm Ther"},{"key":"48_CR41","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/j.1552-4604.1993.tb01950.x","volume":"33","author":"M Kanamaru","year":"1993","unstructured":"Kanamaru M, Uematsu T, Nagashima S, et al.: Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers. J Clin Pharmacol 1993, 33:1122\u20131131.","journal-title":"J Clin Pharmacol"},{"key":"48_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF00271364","volume":"44","author":"B Oosterhuis","year":"1993","unstructured":"Oosterhuis B, Storm G, Cornelissen PJG, et al.: Dose-dependent uricosuric effect of ambroxol. Eur J Clin Pharmacol 1993, 44:237\u2013241.","journal-title":"Eur J Clin Pharmacol"},{"key":"48_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0002-9343(92)90236-5","volume":"93","author":"AG Fam","year":"1992","unstructured":"Fam AG, Lewtas, J, Stein J, Paton TW: Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992, 93:299\u2013302. A preliminary study describing slow oral desensitization to allopurinol, using a schedule of grades doses, in a group of patients allergic to allopurinol who have gout and renal impairment.","journal-title":"Am J Med"},{"key":"48_CR44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/bmj.2.6033.458","volume":"2","author":"A Meyrier","year":"1976","unstructured":"Meyrier A: Desensitization in a patient with chronic renal disease and severe allergy to allopurinol [letter]. BMJ 1976, 2:458.","journal-title":"BMJ"},{"key":"48_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/art.1780280617","volume":"28","author":"E Webster","year":"1985","unstructured":"Webster E, Panush RS: Allopurinol hypersensitivity in a patient with severe chronic tophaceous gout. Arthritis Rheum 1985, 28:707\u2013709.","journal-title":"Arthritis Rheum"},{"key":"48_CR46","first-page":"200","volume":"8","author":"DB Northridge","year":"1986","unstructured":"Northridge DB, Almack PM: Allopurinol desensitization. Br J Pharmaceut Pract 1986, 8:200.","journal-title":"Br J Pharmaceut Pract"},{"key":"48_CR47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/ard.46.8.646","volume":"46","author":"J Unsworth","year":"1987","unstructured":"Unsworth J, Black DR, D\u2019Assis Fonseca AE, Beswick DT: Desensitization to allopurinol: a cautionary tale [letter]. Ann Rheum Dis 1987, 46:646.","journal-title":"Ann Rheum Dis"},{"key":"48_CR48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.46.1.84","volume":"46","author":"SM Kelsey","year":"1987","unstructured":"Kelsey SM, Stuthers GR, Beswick T, Blake DR: Desensitization to allopurinol [letter]. Ann Rheum Dis 1987, 46:84.","journal-title":"Ann Rheum Dis"},{"key":"48_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/ard.46.11.875-a","volume":"46","author":"MG Ridley","year":"1987","unstructured":"Ridley MG, Mathews JA: Desensitization to allopurinol [letter]. Ann Rheum Dis 1987, 46:875.","journal-title":"Ann Rheum Dis"},{"key":"48_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/rheumatology\/38.1.85","volume":"38","author":"TJ Gillott","year":"1999","unstructured":"Gillott TJ, Whallett A, Zaphiropoulos G: Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity [letter]. Rheumatol (Oxford) 1999, 38:85\u201386.","journal-title":"Rheumatol (Oxford)"},{"key":"48_CR51","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.1780341020","volume":"34","author":"BAE Walz-LeBlanc","year":"1991","unstructured":"Walz-LeBlanc BAE, Reynolds WJ, MacFadden DK: Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum 1991, 34:1329\u20131331.","journal-title":"Arthritis Rheum"},{"key":"48_CR52","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1345\/aph.19043","volume":"33","author":"SB Tanna","year":"1999","unstructured":"Tanna SB, Barnes JF, Seth SK: Desensitization to allopurinol in a patient with previous failed desensitization. Ann Pharmacother 1999, 33:1180\u20131183. An interesting case report of a patient with gouty arthritis and renal insufficiency who was successfully re-desensitized to allopurinol after initial failure.","journal-title":"Ann Pharmacother"},{"key":"48_CR53","first-page":"121","volume":"22","author":"M Audicana","year":"1990","unstructured":"Audicana M, Echechipia S, Fernandez E, Urrutia I: Desensitization in a case of fixed eruption from allopurinol [abstract]. Clin Exp Allergy 1990, 22:121.","journal-title":"Clin Exp Allergy"},{"key":"48_CR54","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0091-6749(96)70275-0","volume":"97","author":"JM Kelso","year":"1996","unstructured":"Kelso JM, Keating RM: Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immuno 1996, 97:1171\u20131172.","journal-title":"J Allergy Clin Immuno"},{"key":"48_CR55","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S0091-6749(98)70396-3","volume":"101","author":"A Umpierrez","year":"1998","unstructured":"Umpierrez A, Cuesta-Herranz J, De Las Heras M, Lluch-Bernal M, Figueredo E, Sastre J: Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immunol 1998, 101:286\u2013287. The case report describes a patient successfully desensitized to allopurinol-induced fixed drug eruption.","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl","key":"48_CR56","first-page":"S151","volume":"41","author":"SM Dunne","year":"1998","unstructured":"Dunne SM, Fam AG, Iazzetta J: Efficacy and safety of desensitization to allopurinol following cutaneous reactions [abstract]. Arthritis Rheum 1998, 41(suppl):S151.","journal-title":"Arthritis Rheum"},{"key":"48_CR57","unstructured":"Fam AG, Dunne SM, Iazzetta J, Paton TW: Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum, in press. A retrospective analysis evaluating the outcome, safety, and long-term clinical utility of slow oral desensitization to allopurinol in a larger group of patients with gout and maculopapular eruptions to the drug. The study outlines the indications for allopurinol desensitization and proposed dosing guidelines."},{"key":"48_CR58","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"J-C Ronjeau","year":"1994","unstructured":"Ronjeau J-C, Stern RS: Severe adverse cutaneous reactions to drugs. New Engl J Med 1994, 331:1272\u20131285.","journal-title":"New Engl J Med"},{"key":"48_CR59","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"J-C Ronjeau","year":"1995","unstructured":"Ronjeau J-C, Kelly JP, Naldi L, et al.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New Engl J Med 1995, 333:1600\u20131607.","journal-title":"New Engl J Med"},{"key":"48_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1056\/NEJM198908033210504","volume":"321","author":"H-Y Lin","year":"1989","unstructured":"Lin H-Y, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH: Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989, 321:287\u2013292. A detailed investigation of the mechanisms of cyclosporineinduced hyperuricemia.","journal-title":"N Engl J Med"},{"key":"48_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0002-9343(92)90104-J","volume":"92","author":"DA Burack","year":"1992","unstructured":"Burack DA, Griffith BP, Thompson ME, Kahl LE: Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992, 92:141\u2013146.","journal-title":"Am J Med"},{"key":"48_CR62","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","volume":"11","author":"DM Clive","year":"2000","unstructured":"Clive DM: Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000, 11:974\u2013979. A comprehensive review of cyclosporine-associated hyperuricemia and gout in renal transplant patients.","journal-title":"J Am Soc Nephrol"},{"key":"48_CR63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000188609","volume":"70","author":"R Marcen","year":"1995","unstructured":"Marcen R, Gallego N, Orofino L, et al.: Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995, 70:307\u2013313.","journal-title":"Nephron"},{"key":"48_CR64","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000189328","volume":"74","author":"J Laine","year":"1996","unstructured":"Laine J, Holmberg C: Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron 1996, 74:318\u2013323.","journal-title":"Nephron"},{"key":"48_CR65","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1046\/j.1523-1755.1999.00739.x","volume":"56","author":"S Shahinfar","year":"1999","unstructured":"Shahinfar S, Simpson RL, Carides AD, et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney International 1999, 56:1879\u20131885. A study of the uricosuric effects of losartan in hypertensive patients with thiazide-induced hyperuricemia.","journal-title":"Kidney International"},{"key":"48_CR66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00007890-199807270-00023","volume":"66","author":"G Minghelli","year":"1998","unstructured":"Minghelli G, Seydoux C, Goy J-J, Burnier M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998, 66:268\u2013271.","journal-title":"Transplantation"},{"key":"48_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000045481","volume":"83","author":"M Boran","year":"1999","unstructured":"Boran M, Gonenc F, Cetin S: Losartan in renal allograft recipients receiving cyclosporine A [letter]. Nephron 1999, 83:93\u201394. A preliminary study examining the uricosuric effects of losartan in cyclosporine-treated renal transplant patients.","journal-title":"Nephron"},{"key":"48_CR68","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/00004872-199917070-00021","volume":"17","author":"JG Puig","year":"1999","unstructured":"Puig JG, Mateos F, Buno A, et al.: Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999, 17:1033\u20131039. The study investigates the effects of two angiotensin II receptor antagonists, losartan and eprosartan, on uric acid metabolism.","journal-title":"J Hypertension"},{"key":"48_CR69","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00004872-200018030-00014","volume":"18","author":"P Owens","year":"2000","unstructured":"Owens P, Kelly L, Nallen R, et al.: Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide-a randomized controlled trial. J Hypertension 2000, 18:339\u2013345. The report describes effects of losartan on serum urate levels in patients with hypertension, including those receiving concomitant hydrochlorothiazide.","journal-title":"J Hypertension"},{"key":"48_CR70","first-page":"2232","volume":"27","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Moriwaki Y, Takahashi S, et al.: Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxipurinol and purine bases. J Rheumatol 2000, 27:2232\u20132236. A preliminary short-term study showing that single-dose coadministration of allopurinol and losartan increases the renal excretion of uric acid, xanthine, and oxipurinol.","journal-title":"J Rheumatol"},{"key":"48_CR71","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/00007890-199710150-00027","volume":"64","author":"F Jacobs","year":"1997","unstructured":"Jacobs F, Mamzer-Bruneel MF, Skhiri H, et al.: Safety of mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout [letter]. Transplantation 1997, 64:1087\u20131088.","journal-title":"Transplantation"},{"key":"48_CR72","first-page":"230","volume":"45","author":"LB Hilbrands","year":"1996","unstructured":"Hilbrands LB, Hoitsma AJ, Wetzels JFM, Koene RAP: Detailed study of changes in renal function after conversion from cyclosporine to azathioprine. Clin Nephrol 1996, 45:230\u2013235.","journal-title":"Clin Nephrol"},{"key":"48_CR73","first-page":"50","volume":"27","author":"T Ochiai","year":"1995","unstructured":"Ochiai T, Ishibashi M, Fukao K, et al.: Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995, 27:50\u201353.","journal-title":"Transplant Proc"},{"key":"48_CR74","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0014-2999(93)90033-E","volume":"250","author":"K Komoriya","year":"1993","unstructured":"Komoriya K, Osada Y, Hasegawa M, et al.: Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6729 in chimpanzees. Eur J Pharmacol 1993, 250:455\u2013460.","journal-title":"Eur J Pharmacol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-001-0048-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0048-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:27:43Z","timestamp":1707956863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-001-0048-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s11926-001-0048-8","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}